Shionogi & Co., Ltd. has outlined a policy to halve the drug development period to 3 years before entering clinical trials by using AI drug discovery, and will acquire JT's pharmaceutical business in 2025 to bring in research talent and advanced technologies.
Shionogi & Co., Ltd. has outlined a policy to pursue AI-based drug discovery and reduce the period before a drug enters clinical trials to 3 years as part of the development process.
The initiative is expected to involve AI supporting the new drug development process, including target identification and compound discovery, while making use of advanced technologies such as supercomputers in addition to research talent.
Shionogi & Co., Ltd. plans to acquire Japan Tobacco's pharmaceutical business in 2025, which will accelerate its AI drug discovery efforts using JT's pharmaceutical business as a foundation.